ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00

ArriVent BioPharma (NASDAQ:AVBP) had its target price lifted by investment analysts at Citigroup from $31.00 to $33.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 38.89% from the company’s current price.

AVBP has been the topic of a number of other reports. BTIG Research assumed coverage on ArriVent BioPharma in a research report on Wednesday, December 10th. They set a “buy” rating and a $45.00 target price on the stock. Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. Cantor Fitzgerald started coverage on ArriVent BioPharma in a report on Monday, December 22nd. They set an “overweight” rating on the stock. Truist Financial started coverage on ArriVent BioPharma in a research report on Tuesday, November 25th. They set a “buy” rating and a $43.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, ArriVent BioPharma currently has an average rating of “Moderate Buy” and a consensus target price of $40.44.

ArriVent BioPharma Trading Down 5.9%

NASDAQ:AVBP traded down $1.49 during trading hours on Friday, hitting $23.76. 659,620 shares of the company traded hands, compared to its average volume of 463,975. ArriVent BioPharma has a twelve month low of $15.47 and a twelve month high of $27.22. The firm has a 50-day moving average of $22.17 and a 200 day moving average of $20.89. The stock has a market capitalization of $980.81 million, a price-to-earnings ratio of -5.60 and a beta of 0.99.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.09. Equities research analysts predict that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Trading of ArriVent BioPharma

Institutional investors have recently bought and sold shares of the stock. Bessemer Group Inc. bought a new stake in ArriVent BioPharma in the third quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ArriVent BioPharma by 27.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock worth $40,000 after purchasing an additional 438 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of ArriVent BioPharma by 9,747.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after purchasing an additional 2,047 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after purchasing an additional 609 shares in the last quarter. Finally, Group One Trading LLC bought a new position in ArriVent BioPharma during the 4th quarter valued at about $57,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

ArriVent BioPharma News Summary

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Unusually large call buying: Traders bought ~1,832 call options on Friday (≈321% above typical call volume). Heavy call activity can indicate speculative bullish bets or hedging by sophisticated traders, which may drive short‑term upside interest in the shares.
• Positive Sentiment: HC Wainwright raised its price target from $42 to $44 and maintained a “buy” rating — implying ~83% upside from the cited $24.05 reference price. Analyst optimism and a higher target can attract momentum and institutional interest. Benzinga
• Positive Sentiment: Quarterly EPS beat: AVBP reported (‑$0.78) EPS vs. consensus (‑$0.87), beating by $0.09. An earnings beat for a clinical‑stage biotech reduces short‑term execution risk and can support valuation re‑rating. Earnings Release
• Positive Sentiment: Broker consensus: Coverage summary lists a “Moderate Buy” consensus from brokerages, which reinforces the positive analyst narrative and can support longer‑term inflows. Brokerage Consensus
• Neutral Sentiment: Full‑year 2025 financial results and company update were published (press release). The release provides corporate outlook and financials that investors will parse for cash runway, R&D progress and guidance — important but not an immediate directional catalyst until details are digested. Full Year 2025 Results
• Neutral Sentiment: Short‑interest data reported as zero shares with NaN changes — likely a data anomaly or reporting quirk. This makes short‑interest an unreliable driver currently; absence of meaningful short positions would remove a potential squeeze dynamic.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.